HDAC3 mediates smoking-induced pancreatic cancer. by Edderkaoui, Mouad et al.
UCLA
UCLA Previously Published Works
Title
HDAC3 mediates smoking-induced pancreatic cancer.
Permalink
https://escholarship.org/uc/item/6jf9p02x
Journal
Oncotarget, 7(7)
ISSN
1949-2553
Authors
Edderkaoui, Mouad
Xu, Shiping
Chheda, Chintan
et al.
Publication Date
2016-02-01
DOI
10.18632/oncotarget.6820
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Oncotarget7747www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 7
HDAC3 mediates smoking-induced pancreatic cancer
Mouad Edderkaoui1,2, Shiping Xu2,3, Chintan Chheda1, Susan Morvaridi1, Robert 
W. Hu1, Paul J. Grippo4,5, Emman Mascariñas4,5, Daniel R. Principe4,5, Beatrice 
Knudsen1, Jing Xue6, Aida Habtezion6, Dale Uyeminami7, Kent E. Pinkerton7, 
Stephen J. Pandol1,2
1Departments of Medicine and Biological Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2Veterans Affairs Greater Los Angeles Healthcare System & University of California at Los Angeles, CA, USA
3Department of Gastroenterology, Nanlou Division, The PLA General Hospital, Beijing, China
4Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
5Department of Medicine, University of Illinois-Chicago, Chicago, IL, USA
6 Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, 
CA, USA
7Center for Health and the Environment, University of California, Davis, CA, USA
Correspondence to: Mouad Edderkaoui, e-mail: mouad.edderkaoui@cshs.org
Keywords: smoking, HDAC, pancreatic cancer
Received: November 12, 2015      Accepted: December 22, 2015      Published: January 5, 2016
ABSTRACT
Smoking is a major risk factor for developing pancreatic adenocarcinoma (PDAC); 
however, little is known about the mechanisms involved.
Here we employed a genetic animal model of early stages of PDAC that 
overexpresses oncogenic Kras in the pancreas to investigate the mechanisms of 
smoking-induced promotion of the disease in vivo. We confirmed the regulation of the 
interactions between the tumor microenvironment cells using in vitro cellular systems.
Aerial exposure to cigarette smoke stimulated development of pancreatic 
intraepithelial neaoplasia (PanIN) lesions associated with a tumor microenvironment-
containing features of human PDAC including fibrosis, activated stellate cells, M2-
macrophages and markers of epithelial-mesenchymal transition (EMT). The pro-cancer 
effects of smoking were prevented by Histone Deacetylase HDAC I/II inhibitor Saha.
Smoking decreased histone acetylation associated with recruitment of and 
phenotypic changes in macrophages; which in turn, stimulated survival and induction 
of EMT of the pre-cancer and cancer cells. The interaction between the cancer cells 
and macrophages is mediated by IL-6 produced under the regulation of HDAC3 
translocation to the nucleus in the cancer cells. Pharmacological and molecular 
inhibitions of HDAC3 decreased IL-6 levels in cancer cells. IL-6 stimulated the 
macrophage phenotype change through regulation of the IL-4 receptor level of the 
macrophage.
This study demonstrates a novel pathway of interaction between cancer cells and 
tumor promoting macrophages involving HDAC3 and IL-6. It further demonstrates 
that targeting HDAC3 prevents progression of the disease and could provide a strategy 
for treating the disease considering that the HDAC inhibitor we used is FDA approved 
for a different disease.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the 
fourth leading cause of cancer-related deaths among both 
men and women in the United States and remains without 
effective therapies [1, 2]. Environmental risk factors such 
as smoking, diabetes, obesity and alcoholism play major 
roles in the promotion of PDAC [3-5]. However, we have 
little understanding of how these risk factors promote 
the disease. Animal models expressing genetic changes 
observed in pancreatic cancer have been developed and 
have greatly improved our understanding of the disease. 
However, models incorporating these risk factors have 
been lacking. Because cigarette smoking is an established 
and major risk factor for PDAC [6, 7], models designed 
to determine the mechanisms of smoking-induced PDAC 
can provide important insights into the promotion of this 
cancer.
HDAC enzymes are critical regulators of 
fundamental cellular events such as cell cycle, 
differentiation, and apoptosis [8]. HDAC1 has been shown 
to be involved in regulating epithelial to mesenchymal 
transition (EMT) in pancreatic cancer cells by directly 
interacting and stabilizing the pro-EMT Zeb1 transcription 
factor [9]. EMT is considered a critical process of cell 
transformation in cancer metastasis. In addition to PDAC, 
risk factors such as smoking and alcohol abuse cause 
inflammatory diseases of the pancreas such as acute and 
chronic pancreatitis. Previous reports indicate a key role 
for pancreatic inflammation in the promotion of PDAC 
in both humans and animal models. In addition, there is 
increasing evidence that sub-types of macrophages play 
a major role in promotion of many cancers including 
pancreatic cancer [10, 11]. There is a strong correlation 
between M2 type macrophages and increased metastasis 
and poor prognosis in humans with PDAC [12].
Little is known about the intracellular mechanisms 
involved in secretion of cytokines from early cancer 
lesions such as pancreatic intraepithelial neoplasia 
(PanIN) and cystic papillary neoplasia (CPN similar 
to human IPMN and MCN) and cancer cells that are in 
communication with cells in the tumor microenvironment. 
Data presented here provide evidence for a role of HDAC 
in regulating cytokine secretion involved in promotion of 
the pro-tumor type-2 macrophage (M2) phenotype and 
tumor promotion. That is, inhibition of HDAC specifically 
inhibited interleukin 6 (IL-6) production by cancer 
cells that we found was necessary for the macrophage 
phenotype change in our animal model of PDAC. These 
results point to roles for HDAC and IL-6 in regulation of 
macrophages by neoplastic lesions and cancer cells.
It has been shown that IL-6 is able to induce 
interleukin-4 (IL-4) production in T cells, thereby 
polarizing these cells into Th2 cells [13, 14]. Very little 
is known about the effect of IL-6 on macrophages. Our 
data show a role of IL-6 secreted by the cancer cells on 
inducing the M2 macrophage phenotype.
Multiple human case-control studies have linked 
high serum levels of IL-6 with pancreatic cancer and 
suggested using it as a marker of cancer progression. A 
strong positive correlation was found among tumor stage, 
cachexia and decreased survival [15-20].
In the present study we developed two mouse models 
of pancreatic cancer precursors where Pdx1-Cre;LSL-
Kras (KC) mice were exposed to cigarette smoke in 
smoke chambers. Exposure to cigarette smoke stimulated 
pancreatic neoplasia (PanIN in KC mice) formation 
associated with a tumor microenvironment containing 
features of human PDAC including fibrosis, activated 
stellate cells, M2 macrophages along with markers of 
epithelial to mesenchymal transition (EMT) and cancer 
stemness. We found that HDAC3 plays a major role in 
mediating these smoking pro-cancer effects and that 
inhibition of HDAC3 prevents these effects. Our work goes 
on to demonstrate that HDAC3 specifically regulates IL-6 
production in cancer cells in the tumor microenvironment; 
and that IL-6 is involved in regulating macrophage function 
including the promotion of the M2 phenotype.
RESULTS
Cigarette smoke stimulates PanIN lesions 
formation in KC mice and HDAC inhibition 
reverses this effect
We exposed KC mice to cigarette smoke for 7 
weeks and treated mice with the HDAC inhibitor Saha. 
The KC mice carry the Kras mutation in the pancreas 
and spontaneously develop PanIN lesions, considered to 
be precursors of PDAC [21] Kras mutations are present 
in 90% of pancreatic cancer patients [22, 23]. KC mice 
recapitulate the characteristics of the human disease 
including a vast desmoplastic reaction with rapid growth, 
and represent the early stage of the disease [21]. KC mice 
were exposed to cigarette smoke for 7 weeks and injected 
with Saha or saline during the last 5 weeks of the treatment 
(Fig 1A). During the 7 weeks of smoking exposure, levels 
of carbon monoxide and gravimetric total smoke particles 
(TSP) were measured every day and the levels of nicotine 
measured every week (Table 1). TSP was increased during 
the first week gradually to reach 80mg/m3.
Analysis of the pancreatic tissue from KC mice 
exposed to cigarette smoke showed a marked increase 
in the number and tissue area occupied by PanIN lesions 
compared to control treated mice. The tissue area 
containing PanINs was increased by over 300% and the 
number of lesions was increased by ~70% (Fig 1B-1D). 
More importantly, this increase was abolished when mice 
were exposed to HDAC inhibitor Saha. The number and 
tissue area covered by PanINs was decreased to a level 
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less than in control mice suggesting that HDAC not only 
mediated the smoking effect but also contributed in the 
basal progression of the disease (Fig 1C, 1D).
Other characteristics of pancreatic cancer such 
as fibrosis and stellate cells activation were stimulated 
by cigarette smoke, and prevented by Saha (Fig 
2A, 2B). Collagen staining showed an increase of 
35% and α-SMA by 2.5 times. Saha reversed these 
effects decreasing collagen and α-SMA level by 70% 
(Fig 2A, 2B).
Furthermore, dual staining of macrophages by 
the general marker F4/80 and M2 macrophage marker 
Arginase1 showed a 30% increase in the M2 macrophages 
in the pancreas of mice exposed to cigarette smoke (Fig 
2E). The increase in the number of M2 macrophages 
was nearly abolished by Saha and was decreased by 
almost 90% (Fig 2F). In addition, we found that smoking 
stimulated EMT in mice pancreas as shown by E-cadherin 
staining of the pancreatic tissue. This effect was inhibited 
with Saha (Fig 2G).
In sum, the results above indicate that exposure 
to cigarette smoke stimulates PanIN lesion formation, 
fibrosis and inflammation, especially the presence of 
M2 macrophages, and EMT. More importantly, the 
administration of Saha to inhibit HDAC prevented these 
pro-cancer effects of smoking.
Interaction between PanIN/cancer cells and M2 
macrophages mediates promotion of pancreatic 
cancer
Strong evidence shows a pro-cancer role of M2 
macrophages in tumor development and worse outcome 
in pancreatic cancer patients [24]. Therefore, we 
established studies to analyze the potential interactions 
between macrophages and pancreatic cancer cells. 
We found that the pancreatic cancer cell line MIA 
PaCa-2 conditioned media increased the survival of 
macrophages (Fig 3A) and more importantly stimulated 
a phenotype change of the macrophages towards the 
Figure 1: Cigarette smoke exposure stimulates pancreatic lesion formation and HDAC inhibition prevents this effect 
in KC mice. KC mice were exposed to cigarette smoke or filtered air for 7 weeks and injected with saline or Saha (50mg/Kg) 5 days a 
week during the last 5 weeks A. B. H&E staining of the pancreas of the KC mice exposed to filtered air (a, d) or cigarette smoke (b, e) or 
cigarette smoke with injections of HDAC inhibitor Saha (c, f). C. Quantification of tissue area occupied by PanIN lesions. D. Quantification 
of the number of PanIN lesions per tissue area. *p < 0.05 versus control. #p < 0.05 versus cigarette smoke.
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Carbon Monoxide 
(ppm)
CO StdDev  
(ppm)
Nicotine  
(mg/m3)
Gravimetric 
TSP (mg/m3)
TSP StdDev  
(mg/m3)
Day 1 157.73 11.04 41.31 2.29
Day 2 172.50 11.37 50.55 3.36
Day 3 217.27 7.86 12.10 65.76 3.26
Day 4 216.36 11.42 63.77 7.60
Day 5 230.91 18.41 70.47 7.75
Day 8 243.64 8.69 75.00 6.05
Day 9 240.00 10.00 73.67 2.55
Day 10 264.09 5.84 13.70 83.58 3.02
Day 11 263.33 6.61 82.61 6.15
Day 12 265.91 13.75 85.51 7.67
Day 15 255.00 11.55 83.57 3.99
Day 16 229.09 8.01 75.12 3.43
Day 17 166.25 9.16 48.31 6.33
Day 18 167.14 3.93 50.48 2.33
Day 19 188.64 8.39 9.40 56.28 2.74
Day 22 230.00 9.57 63.77 3.84
Day 23 205.71 14.84 64.73 5.44
Day 24 213.18 6.03 71.38 2.81
Day 25 214.44 3.91 10.40 71.01 1.45
Day 26 211.82 5.13 73.43 3.02
Day 29 215.00 2.89 68.36 7.69
Day 30 213.64 3.23 66.36 1.67
Day 31 216.67 6.12 66.67 2.62
Day 32 233.64 7.45 8.80 80.44 8.17
Day 33 235.56 11.30 74.16 5.81
Day 36 231.36 8.97 71.74 2.51
Day 37 234.00 15.78 11.90 62.56 3.58
Day 38 244.09 16.40 69.56 5.07
Day 39 237.73 6.84 11.90 82.97 4.68
Day 40 232.73 5.18 71.50 7.26
Day 43 252.78 11.76 65.94 6.91
Day 44 239.55 8.50 9.70 81.64 5.86
Day 45 238.33 5.59 82.61 4.75
Day 46 247.50 6.12 76.54 6.79
Day 47 256.67 4.08 73.14 6.22
Mean: 225.21 8.73 10.86 70.11 4.7
StDev 27.87 3.91 1.76 10.82 2.04
Table 1: Measurements of Carbon Monoxide (CO) and total smoke particles (TSP)
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M2 phenotype as measured by its markers CD163 and 
Arginase1 (Fig 3B). Next, we cultured pancreatic cancer 
cell lines in the presence of macrophage conditioned 
media and found that M2 macrophage conditioned media 
promoted survival of both MIA PaCa-2 and Bx-PC3 cells 
compared to the M1 macrophage conditioned media (Fig 
3C). In addition, M2 macrophage conditioned media 
stimulated EMT in pancreatic cancer cells as shown by 
measuring the level of the EMT markers N-cadherin and 
vimentin (Fig 3D). Of note, E-cadherin, N-cadherin, and 
vimentin measurements we used in the previous figures 
are established markers of EMT [25].
p-HDAC3 and IL-6 mediate the interaction 
between cancer cells and macrophages
The results in Fig 3 led us to investigate the 
composition of the cancer cell conditioned media to 
determine what mediates the change in macrophage 
phenotype induced by the cancer cells.
Therefore, we analyzed the growth factors and 
cytokines secreted by cancer cells in the presence and 
absence of HDAC inhibition using multiplex analysis. We 
found that Saha did not affect production of any of the 
analytes except the cytokine IL-6, suggesting that IL-6 
Figure 2: Cigarette smoke exposure stimulates fibrosis, macrophage M2 phenotype induction and EMT in the pancreas 
of KC mice. A. Sirius Red/Collagen staining of the pancreas of KC mice exposed to filtered air or cigarette smoke with or without 
HDAC inhibitor Saha. C. α-SMA staining of mice pancreas. E. Macrophage dual staining with F4/80 and Arginase1. G. E-cadherin 
staining of mice pancreas. (B, D, F, H) Quantification of the staining in the right of each panel. *p < 0.05 versus control. #p < 0.05 versus 
cigarette smoke.
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Figure 3: Interaction between cancer cells and macrophages. Cells were cultured for 24h and then conditioned media applied 
to the other cell type for 24h. A. Cell survival of macrophages cultured in MIA PaCa-2 conditioned media measured by MTT assay. 
B. Protein levels of CD163 and Arginase1were measured by Western in the lysates of macrophages cultured in MIA PaCa-2 conditioned 
media; Blots were re-probed for PanActin to confirm equal loading. C. Cell survival of MIA PaCa-2 and Bx-PC3 cells cultured in M1 and 
M2 macrophage conditioned media measured by MTT assay. D. Protein levels of N-cadherin and vimentin were measured by Western in 
lysates of MIA PaCa-2 cells cultured in M0/M1 or M2 macrophage conditioned media; blots were re-probed for PanActin to confirm equal 
loading. *p < 0.05 versus control.
mediates the regulation of the macrophage phenotype by 
cancer cells (Fig 4).
To determine which member of the HDAC 
families I and II (inhibited by saha) is involved in 
regulating IL-6 production we analyzed the protein 
level and localization of members of both families. We 
found that HDAC3 phosphorylation level as well as the 
level of p-HDAC3 in nuclear extracts were significantly 
increased by both NNK and Cigarette Smoke 
Condensate (CSC) smoking compounds (Fig 5A). The 
level of total HDAC3 in total lysates did not change (Fig 
5A) indicating that smoking compounds affect only the 
phosphorylation status and the translocation of HDAC3 
to the nucleus but not its protein level.
Next, we measured the effect of smoking 
compounds on secretion of IL-6 by the cancer cells. 
We found that NNK increased the level of IL-6 in 
MIA PaCa-2 conditioned media by up to 3 folds 
(Fig 5B). This effect was abolished when applying a 
pharmacological or molecular inhibition of HDAC3 
(Fig 5B).
To confirm the regulation of macrophage phenotype 
by IL-6 we added IL-6 to the macrophages and found 
that IL-6 increased the M2 phenotype as measured by 
the level of two M2 macrophages markers Arginase1 
and CD163 consistent with the in vitro and in vivo results 
described above (Fig 6A). One mechanism through 
which IL-6 may mediate macrophage phenotypic 
change is through up-regulation of the IL-4 receptor 
level [26]. Results in Fig 6B show that exposure of 
human macrophages, pre-incubated for 24h with IL-4, to 
recombinant IL-6, indeed, increases the number of cells 
expressing IL-4 receptor from 62% to 91% of the total 
population of macrophages (Fig 6B).
p-HDAC3, IL-6, M2 macrophages, and IL-4 
receptor were highly expressed and histone 
acetylation decreased in human pancreatic 
tumors
To verify the validity of our animal and in vitro 
data in humans we measured the protein level of histone 
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Figure 4: Multiplexing analysis of the secretions of pancreatic cancer cells. A. Multiplexing analysis of growth factors, 
cytokines and chemokines expressed and secreted in the media by MIA PaCa-2 cells cultured for 24h in the presence of absence of HDAC 
inhibitor Saha. Data is representative of 3 different measurements that give similar results.
acetylation in human pancreatic cancer tissue samples 
and their matching pancreatic normal-appearing tissues 
from the same patients. We found that histone acetylation 
was decreased in all cancer tissues compared to their 
matching normal tissues (Fig 7A). Similarly, protein level 
of p-HDAC3 was increased in 4 out of 5 human cancer 
tissue samples compared to their matching normal-looking 
tissues (Fig 7A). Furthermore, staining of pancreatic 
tissue samples from cancer and normal patients showed 
increase in the level of IL-6 cytokine, M2 macrophages, 
and IL-4 receptor levels on macrophages as measured 
by immunostaining (Fig 7B). Of note, IL-6 staining was 
observed in many cell types in the cancer tissue including 
cancer cells and stellate cells compared to almost no 
staining in normal tissue. The role of stellate cells in 
the micro-environment cell interactions is investigated 
in a separate study. Quantification of the number of M2 
macrophages shows a significant 2.5-times increase in 
cancer tissue compared to normal tissue (Fig 7C). The 
number of M2 macrophages (dual positive for CD68 and 
Arginase1) was increased by 15 times in cancer tissue 
(30% of total macrophages) compared to normal tissue 
(2% of total macrophages) (Fig 7C). Furthermore, the 
level of IL-4 receptor staining in M2 macrophages was 
increased from 30% of M2 macrophages in normal tissues 
to 81% in cancer tissues (Fig 7B). All these data in human 
tissue samples confirm our findings in mice.
DISCUSSION
In this study we have developed a model of early 
PDAC induced by smoking, a major risk factor for the 
disease. We used genetically altered animals for this model 
using the Pdx1-Cre;LSL-Kras mice which spontaneously 
develop PanIN lesions [21], the precursors of PDAC. 
Here we provide information in these genetically altered 
animals that exposure to cigarette smoke promotes these 
precancerous lesions through a mechanism that involves 
HDAC, especially p-HDAC3.
First, cigarette smoke induced a significant 
stimulation in the amount and the size of pancreatic 
lesions. Associated with neoplasia development were 
several other features of human PDAC including a tumor 
microenvironment consisting of fibrosis, activated stellate 
cells, and M2 macrophages along with markers of EMT. 
Cigarette smoke exposure induced a significant 8-fold 
increase in pancreatic lesions. Cigarette smoking induced 
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Figure 6: IL-6 up-regulates macrophage M2 phenotype and stimulates IL-4 receptor expression. A. Human macrophages 
were cultured in the presence of IL-6 (20 ng/ml) for 24h and the level of Arginase1 and Cd163 measured by Western. Blots were re-probed 
for GAPDH to confirm equal loading. B. Human macrophages were cultured in the presence of IL-6 (20 ng/ml) for 24h and the level of 
IL-4 receptor measured by flow cytometry.
Figure 5: Smoking stimulates IL-6 production through a mechanism that involves HDAC3 translocation to the nucleus. 
MIA PaCa-2 cells were incubated for 1h in the presence or absence of smoking compounds NNK and CSC or in the presence of HDAC3 
specific inhibitor RGFP966 (1μM). A. Protein level of p-HDAC3 in nuclear extracts and total lysates is measured by Western. Blots were 
re-probed for H3 histone or GAPDH to confirm equal loading. B. Cells were cultured with NNK (1 μM) for 48h and IL-6 level measured by 
multiplexing. MIA PaCa-2 cells were transfected with scrambled or HDAC3 siRNA using the electroporation Amaxa System Nucleofector 
according to the manufacturer protocol. *p < 0.05 versus control. #p < 0.05 versus NNK.
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an increase of 30% in fibrosis. In KC mice, the increase 
in collagen deposition was associated with an increase 
in stellate cells activation. Stellate cells are considered 
responsible for the large amount of collagen production in 
the tumor micro-environment [27-29].
Further analysis focused on the presence of the 
macrophages, especially M2 macrophages showed a 30% 
increase in their number in the KC mice exposed to cigarette 
smoke compared to KC mice exposed to filtered air.
We observed a general tendency of an increase 
in the level of M2 macrophages in mice exposed to 
cigarette smoke compared to control treated mice. The 
effect of smoking on macrophages confirms the recently 
published findings in a mice model of pancreatic 
cancer [30].
A very important finding of the study is that smoking 
can mediate EMT at the stage of pancreatic lesions, long 
before reaching the adenocarcinoma stage. Markers of 
EMT such as a decrease in E-cadherin and increase in 
vimentin were stimulated by cigarette smoke. This is 
crucial finding knowing the association between EMT and 
metastasis and cancer stemness [31, 32].
The role of HDAC and macrophages in promoting 
pancreatic cancer development was investigated in our 
study. We found that smoking decreased histone acetylation 
in a similar fashion. Further, we found that inhibition of 
HDAC prevents neoplastic lesion formation, fibrosis, and 
M2 macrophage in the KC mice exposed to cigarette smoke.
Our in vitro data showed that among the HDAC 
family HDAC3 mediates a critical interaction between 
Figure 7: Relationship between histone acetylation, p-HDAC3, IL-6, macrophage phenotype and IL-4 receptor in 
human tissue samples. A. Levels of acetylated H3 histones and p-HDAC3 were measured by Western in human tissue samples from 
pancreatic tumors and their matching normal-appearing tissues (from the same patient). Blots were re-probed for Erk to confirm equal 
loading. B. Immuno-fluorescence staining of IL-6, Arginase1, IL-4 receptor and dual staining for Arginase1 and IL-4 receptor in normal 
and cancer human pancreatic tissues. C. Quantification of the cells stained positive for M2 macrophages (CD68 and Arginase1) and 
macrophage expressing IL-4 receptor (CD68 and IL-4 receptor).
Oncotarget7756www.impactjournals.com/oncotarget
cancer cells and macrophages leading to stimulation 
of the macrophage phenotype change towards the pro-
cancer M2 phenotype. This effect is mediated by the IL-6 
cytokine. We found that smoking compounds stimulate 
activation/phosphorylation and translocation of HDAC3 
to the nucleus, and that pharmacological and molecular 
inhibitions of HDAC3 decrease the level of IL-6 produced 
by the cancer cells. IL-6 mediated, at least in part, the 
phenotypic change in macrophages through regulation of 
IL-4 receptor expression leading to more interaction with 
IL-4 in the micro-environment. The HDAC3 regulation 
of IL-6 in the pancreatic cancer cells and its effect on 
regulating the macrophage phenotype is a novel finding.
The pro-tumor M2 macrophages in turn, slightly, but 
significantly, stimulated survival of the pancreatic cancer 
cells. More importantly, we found that M2 macrophage 
conditioned media stimulated expression of EMT markers 
in pancreatic cancer cells. This effect could be mediated 
by TGF-β and IL-10 [11, 33].
EMT is an important mediator of early metastasis 
and resistance to treatments indicating development of 
these features of cancer aggressiveness in early stages of 
the disease [31, 32, 34].
The analysis of human pancreatic tissue samples 
confirmed our findings in animals and cells. The pancreatic 
cancer tissue samples were compared to their matching 
tissue samples isolated from the normal looking pancreatic 
tissue areas from the same patient. Human pancreatic cancer 
tissues expressed lower levels of histone acetylation, higher 
level of p-HDAC3 and M2 macrophage marker Arginase1, 
and higher levels of IL-6 and IL-4 receptor compared 
to normal tissue. This is the first data showing such 
associations in the human pancreatic cancer tissue samples.
Recently published data showed that inhibition 
of IL-6 prevents promotion of pancreatic cancer in 
mice [35]. Our data show the mechanism of regulation 
of IL-6 production in the context of pancreatic cancer 
development through a pathway that involves HDAC3 
activation.
Preventing EMT is of critical importance in the 
fight against pancreatic cancer. In fact, chemotherapeutic 
agents are very successful in killing and preventing 
proliferation of the cancer cells; yet, EMT-mediated 
metastasis and cancer stemness induce a rapid spreading 
of the disease in the body as well as a rapid development 
of resistance to treatments. Therefore, our findings 
open a possibility to target these key components of the 
pathway mediating cancer cell evasion from treatments. 
This study shows a critical role of IL-6 in mediating 
the interaction between cancer cells and macrophages. 
However, we cannot exclude that IL-6 is also produced 
by macrophages and pancreatic stellate cells and 
may regulate other interactions, especially involving 
pancreatic stellate cells [36].
In summary, we have developed an animal model 
of pancreatic cancer precursors induced by a combination 
of a genetic mutation and exposure to cigarette smoke. 
An important finding of the study is the role of HDAC 
in promoting pancreatic cancer through a mechanism that 
involves stimulation of the interaction between pre-cancer 
or cancer cells and macrophages. This mechanism is 
mediated by HDAC3 and IL-6 (Fig 8). More importantly, 
we found that inhibition of HDAC by the FDA approved 
inhibitor Saha reversed the effect of smoking and 
decreased the level of PanIN lesions along with inhibition 
of development of the tumor microenvironment. These 
Figure 8: Representative scheme of the effect of smoking on p-HDAC3 leading to a cross talk between cancer cells 
and macrophages and promotion of the cancer.
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results demonstrate a novel mechanism of cancer 
promotion through regulation of histone acetylation. They 
also demonstrate a novel mechanism of regulation of the 
macrophages phenotype leading to a phenotype change 
in the cancer cells towards the mesenchymal phenotype 
prone of metastasis and resistance to treatments.
EXPERIMENTAL PROCEDURES
Reagents
NNK was purchased from ChemSyn Science 
Laboratories (Lenexa, KS, USA). Cigarette smoke 
condensate (CSC) from Murty Pharmaceuticals Inc 
(Lexington, KY). Alpha-smooth muscle actin (αSMA) 
antibody was purchased from Sigma-Aldrich (St. Louis, 
MO); CD45 antibody from Thermo-Scientific (Rockford, 
IL); Sirius Red/Collagen Staining Kit was from Chondrex 
(Redmond, WA); F4/80 and vimentin antibodies from 
AbCam (Cambrige, MA); Arginase1 from Santa Cruz 
Biotechnology (Santa Cruz, CA); IL-6 antibody from 
Novus Biological (Littleton, CO); IL-4 receptor-α antibody 
from Biolegend (San Diego, CA); other antibodies 
were from Cell signaling (Danvers, MA). IL-4 and IL-6 
recombinant peptides were from Bio Vision (Milpitas, 
CA). M-CSF was from Prospec (East Brunswick, NJ). 
Saha was from Cayman (Ann Arbor, MI). All other 
chemicals were from Sigma Aldrich (St. Louis, MO).
Mouse model
Mice were generated by Dr. Paul Grippo [21, 37]. 
Mice were housed in a temperature of (20 -/+2°C) room 
with a 12 hour light-dark cycle.
The Pdx1-Cre;LSL-Kras mice (8 mice per group) 
were exposed to cigarette smoke for 6 hours per day, 5 
days per week for duration of 7 weeks. We used humidified 
3R4F cigarettes (Tobacco Health Research Institute, 
Lexington, KY). During the first week, the concentration 
of nicotine in the smoke was raised every day from 
30mg/m3 to reach 80mg/m3 by the end of the week to 
allow adaptation of the mice to the treatment. During the 
remaining 6 weeks mice were exposed to cigarette smoke 
for an average level of 80mg/m3. The concentration of 
nitric oxide and carbon monoxide in cigarette smoke in 
the chambers was monitored daily. The level of nicotine 
was measured weekly during the remaining 6 weeks of 
the treatment.
During the last 5 weeks of the exposure mice were 
intra-peritoneally (i.p.) injected with Saha (50mg/Kg) or 
saline 5 days per week [38].
After 7 weeks, mice were sacrificed 24 hours after 
the last exposure to cigarette smoke, pancreas collected 
and preserved adequately for analysis.
All of the mice were housed in Association 
for Assessment and Accreditation of Laboratory Animal 
Care-accredited facilities and used in accordance with the 
NIH Guide for Care and Use of Laboratory Animals.
Luminex assay
Luminex assay was performed at Stanford Human 
Immune Monitoring Center as recommended by the 
manufacturer (Panomics/Affymetrix). Assays were 
performed in duplicate using the Luminex 200 IS System 
(Luminex Corp.) as reported previously [39]. Individual 
cytokines and chemokines were identified and classified 
by the red laser, and levels were quantified using the green 
laser. Digital images of the bead array were captured after 
laser excitation and processed on a computer workstation. 
Standard curves and reports of unknown samples were 
prepared using BeadView and MiraiBio software.
Human pancreatic tissue samples
Human pancreatic tissue samples were received 
from Dr. Nissen, the Director of Hepatobiliary and 
Pancreatic Surgery at Cedars-Sinai Medical Center. The 
study is approved by Cedars-Sinai under the IRB protocols 
# 4201and # 34086. Informed consents were obtained 
from all subjects before collecting tissue specimens.
Macrophage preparation
For Bone Marrow Derived Macrophage (BMDM) 
preparation, in brief, both ends of femur and tibia were 
cut and flushed with a syringe filled with complete 
RPMI 1640 containing 10% fetal bovine serum (cRPMI) 
to extrude BM cells into a sterile petri dish. After gentle 
re-suspension and centrifugation, BM cells were cultured 
using 20% L929 cell conditioned medium (as a source 
of granulocyte/macrophage colony-stimulating factor) 
in cRPMI. On day 4, unattached cells were discarded, 
and medium was replaced with a fresh batch containing 
the L929 cell conditioned medium as above. Cells were 
ready for use on day 6 [40]. For human macrophage 
preparation, in brief, human peripheral blood mononuclear 
cells (PBMCs) were isolated from buffy coats by Ficoll-
Hypaque density gradient centrifugation, and then 
monocytes were further enriched by CD14+ magnetic 
beads (Miltenyi Biotec). Enriched monocytes were 
cultured with complete RPMI medium containing 50-100 
ng/ml hM-CSF for 6 days. At day 7, human macrophages 
were ready for use [41].
Immunohistochemistry
Samples of pancreas were fixed in formalin and 
paraffin embedded. Paraffin-embedded sections of 
pancreas were stained with hematoxylin and eosin to 
determine the presence of pancreatic lesions and for 
standard histological examination. Fibrosis was evaluated 
by immunostaining with Sirius Red/Collagen antibody 
Oncotarget7758www.impactjournals.com/oncotarget
and activated stellate cells identified by αSMA staining. 
Inflammatory cells in the pancreas were evaluated 
by immunostaining with anti-CD45 antibody. Cell 
proliferation was evaluated by PCNA staining.
Immunofluorescence analysis
Immunofluorescence analysis of the pancreas after 
smoke exposure was performed on 5-μm-thick tissue 
sections mounted onto glass slides that were baked 
overnight at 58°C. Tissues were deparaffinized with 
xylene, rehydrated in decreasing concentrations of ethanol 
and permeabilized for 30 min with methanol solution. 
Antigen retrieval was performed by boiling sections in 
0.5% citrate buffer for 15 min, blocked with 2.5% horse 
serum for 1 h and incubated with murine F4/80 and 
Arginase1 (Santa Cruz Biotechnology, Santa Cruz, CA) 
primary antibodies overnight at 4°C. Slides were washed 
with PBS and incubated with FITC-conjugated (A-629511, 
Invitrogen, Grand Island, NY, USA) and Alexa-Fluor-647 
(A-21447, Invitrogen)-conjugated secondary antibodies 
for 1 h, washed three times and mounted with Vectashield 
containing 4ʹ 6ʹ-diamidino-2-phenylindole (DAPI).
Western blot
Tissue was homogenized and re-suspended in RIPA 
phosphorylation buffer (50 mM NaCl, 50 mM Tris/HCl 
pH 7.2, 1% deoxycholic acid, 1% Triton X-100, 0.1% 
SDS, 10 mM Na2HPO4 + NaH2PO4, 100 mM NaF, 2 mM 
Na3VO4, 80 μM glycerophosphate, 20% glycerol, 1 mM 
PMSF, 5 μg/ml each of pepstain, leupeptin, chymostatin, 
antipain, and aprotinin), sonicated and centrifuged for 
15 min at 16,000 x g at 4°C. Proteins in the supernatant 
were separated by SDS-PAGE and electrophoretically 
transferred to nitrocellulose or PVDF membranes. Non-
specific binding was blocked for 1 h with 5% bovine 
serum albumin or non-fat dry milk in Tris-buffered saline 
(4 mM Tris base, 100 mM NaCl, pH 7.5) containing 
0.05% Tween 20. Membranes were incubated with 
primary antibody overnight at 4°C, and then for 1 h with 
peroxidase-conjugated secondary antibody. Blots were 
developed using Supersignal Chemiluminescent Substrate 
(Pierce, Rockford, IL).
Cell culture and transfection
The poorly differentiated MIA PaCa-2 and 
moderately differentiated Bx-PC3 human pancreatic 
adenocarcinoma cell lines were obtained from the 
American Type Culture Collection (Manassas, VA). MIA 
PaCa-2 cells were grown in 1/1 D-MEM/F-12 medium 
(GIBCO Invitrogen Corporation, Grand Island, NY) 
supplemented with 15% fetal bovine serum (FBS), 4 mM 
l-glutamine, and 1% of antibiotic/antimicotic solution 
(Omega Scientific, Tarzana, CA). Bx-PC3 were grown 
in RPMI-1640 (GIBCO Invitrogen Corporation, Grand 
Island, NY) supplemented with 10% fetal bovine serum 
(FBS) and 1% of antibiotic/antimicotic solution (Omega 
Scientific, Tarzana, CA). Cells were maintained at 37°C 
in a humidified atmosphere containing 5% CO2 and were 
used between passages 2 and 10.
Transient transfections of MIA PaCa cells were 
performed using the electroporation Amaxa System 
Nucleofector™ (Amaxa Inc, Gaithersburg, MD) according 
to the manufacturer protocol. HDAC3 siRNA, (MWG 
biotech, High Point, NC) was applied to the cells using 
electroporation according to the Amaxa kit protocol. 
Control cells were transfected with the Silencer Negative 
Control siRNA #1 (Ambion; Foster City, CA).
Flow cytometry
For surface staining, cells were stained with 
APC-conjugated IL-4 receptor-α (Biolegend). Cells 
were washed, stained with surface markers. Dead cells 
were excluded from analysis using violet viability stain 
(Invitrogen). Cells were acquired on a Cyan (Beckman 
Coulter, Brea, CA) and analyzed with Summit v4.3.
Statistics
Statistical analyses of the immunohistochemical 
quantifications and biochemical measurements were 
performed by using Student’s t test, one-way ANOVA, 
or Fisher’s exact test with GraphPad Prism (GraphPad 
Software). A p value < 0.05 was considered statistically 
significant. The data showed is the result of at least 3 
different experiments.
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